Asep Darmawan
By Judy George, Deputy Managing Editor, MedPage Today
October 21, 2026
In a pioneering exploration of psychedelic medicine, researchers have uncovered evidence that psilocybin therapy—typically associated with mental health treatment—may offer tangible biological benefits for patients living with Parkinson’s disease. A recent small-scale, nonrandomized clinical trial has revealed that psilocybin administration is linked to a measurable reduction in markers of systemic inflammation and mitochondrial stress in individuals suffering from Parkinson’s-related mood dysfunction.
This study, published in JAMA Psychiatry, represents a significant shift in how the medical community views the potential of psychedelic compounds. While the psychiatric community has long focused on the efficacy of psilocybin for depression, anxiety, and addiction, this research marks the first time such therapy has been evaluated for its impact on the physiological markers of a neurodegenerative disorder.
The Core Findings: A Shift in Biological Markers
The research, led by Ellen Bradley, MD, of the University of California San Francisco (UCSF), focused on 12 patients with mild-to-moderate Parkinson’s disease, ranging in age from 40 to 75. By examining plasma samples taken at various intervals, the researchers sought to quantify changes in the body’s inflammatory response and mitochondrial health following the administration of synthetic psilocybin.
The study utilized a "proinflammatory index," a calculated mean z-score of several key biomarkers, including interleukin (IL)-6, IL-8, tumor necrosis factor alpha (TNF-α), interferon-gamma, and high-sensitivity C-reactive protein (hs-CRP).
The results were statistically significant. Compared to baseline levels, the inflammatory index was notably lower across all follow-up time points after psilocybin administration. Specifically, the standard mean difference (SMD) was -0.72 (adjusted P=0.003) just 24 hours after a 10-mg dose of psilocybin. The impact remained evident following a higher dose of 25 mg, with an SMD of -0.60 (adjusted P=0.02) at the 1-day mark, and an SMD of -0.62 (adjusted P=0.047) 30 days post-administration.
Chronology of the Clinical Trial
The trial was structured to observe both immediate and sustained biological responses to the drug. The 12 participants underwent an open-label process involving two distinct doses of oral synthetic psilocybin, administered approximately two weeks apart.
- Baseline Assessments: Before the first dose, the research team established a baseline for each participant’s systemic inflammation and mitochondrial stress markers.
- Initial Intervention (10 mg): Participants received an initial dose of 10 mg. Plasma samples collected 24 hours later showed a significant reduction in the proinflammatory index and a specific, localized impact on IL-6 levels.
- Secondary Intervention (25 mg): Two weeks after the initial dose, participants were given a 25-mg dose. Researchers noted that mitochondrial stress markers, specifically growth differentiation factor 15 (GDF-15), were significantly lower 24 hours after this administration compared to baseline.
- Long-term Monitoring: The final plasma collection occurred 30 days after the 25-mg dose, where the reduction in the proinflammatory index remained statistically significant, suggesting that the physiological "calming" effect of the therapy may persist beyond the immediate acute experience of the drug.
Mitochondrial Stress and Inflammation: The Biological Mechanism
The study did not only look at inflammation; it also investigated mitochondrial stress. Mitochondria are the powerhouses of the cell, and their dysfunction is a hallmark of many neurodegenerative diseases, including Parkinson’s.
To evaluate this, Bradley’s team measured GDF-15 and fibroblast growth factor 21 (FGF-21). While GDF-15 levels dropped significantly following psilocybin administration, FGF-21 levels showed an increase 24 hours after dosing, though this specific finding did not reach statistical significance.
"To our knowledge, this is the first report of changes in these types of markers after psychedelic treatment in people with a neurodegenerative disease," Dr. Bradley explained in an interview with MedPage Today. "That gives us and other researchers super-interesting biological questions to pursue: What could be producing these changes, are they consistent in larger groups of people, and do they have anything to do with clinical benefits people with Parkinson’s might experience with psilocybin?"
Expert Perspectives: A Growing Field of Inquiry
The implications of this study reach far beyond the immediate Parkinson’s community. Albert Garcia-Romeu, PhD, of the Johns Hopkins University School of Medicine, who was not involved in the trial, views these findings as part of a larger, evolving narrative regarding the therapeutic scope of psychedelics.
"Much of the work looking at psilocybin or LSD has focused squarely on mental health conditions like depression, anxiety, or addiction," Garcia-Romeu noted. "However, this study is in patients with a neurological condition—Parkinson’s disease—and shows evidence that psilocybin may have impacted biological markers of inflammation and mitochondrial stress."
He pointed out that this research arrives shortly after findings in preclinical models—such as mice studies—suggested that psilocybin could potentially block nerve damage related to chemotherapy. According to Garcia-Romeu, these new data suggest that the biological effects of psychedelics could be the engine driving clinical benefits. He believes this paves the way for a more rigorous, mechanistic understanding of how these compounds might serve as viable therapeutics for non-psychiatric, systemic conditions.
Implications for Future Research and Patient Care
While the findings are undeniably "highly promising," the authors are careful to advise caution. Co-author Aoife O’Donovan, PhD, of UCSF, emphasized that the small sample size—nine participants who provided usable plasma data—means these findings should be viewed as preliminary.
"We are already following this study up with more in-depth analyses of the effects of psilocybin therapy on inflammation and mitochondrial stress in a randomized controlled trial in patients with Parkinson’s disease," O’Donovan stated.
The transition from open-label, small-group trials to randomized, placebo-controlled trials is the necessary next step for validating whether psilocybin can reliably alter the trajectory of Parkinson’s disease. If confirmed in larger cohorts, the ability to modulate systemic inflammation through psychedelic therapy could represent a paradigm shift in how neurodegenerative conditions are managed.
Beyond Parkinson’s, the field is already expanding. Dr. Garcia-Romeu’s laboratory is currently conducting a trial focusing on patients with mild cognitive impairment and early-stage Alzheimer’s disease who also suffer from depression. With 18 of 20 targeted patients already treated, the academic community anticipates further clarity on the neurological and systemic reach of these therapies by next year.
Conclusion: A New Frontier
The intersection of psychedelic science and neurology is still in its infancy, yet the data from Dr. Bradley’s team offers a compelling new hypothesis: that the therapeutic benefits of psilocybin are not merely psychological or subjective, but deeply biological. By addressing systemic inflammation and mitochondrial dysfunction, psilocybin may be doing more than just improving a patient’s mood—it may be engaging with the underlying pathology of Parkinson’s disease itself.
As the medical community awaits the results of larger, randomized controlled trials, the current study stands as a foundational piece of evidence, suggesting that the potential for psilocybin in the clinical setting is limited only by our current understanding of its complex interactions with human physiology. For the millions of people living with neurodegenerative diseases, this research offers a glimpse into a future where treatment options may eventually address both the mind and the cellular mechanics of the disease.
Reynand Wu
Sagoh
